株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

harmaPoint:脂質異常症 - 世界の医薬品予測・市場分析

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

発行 GlobalData 商品コード 336855
出版日 ページ情報 英文 356 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
harmaPoint:脂質異常症 - 世界の医薬品予測・市場分析 PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025
出版日: 2016年12月13日 ページ情報: 英文 356 Pages
概要

世界における脂質異常症 (高脂血症) 治療薬の市場規模は、2013年に154億米ドルとなり、ブランド薬の売上が110億米ドル (72%) 、ジェネリック薬の売り上げが44億米ドル (28%) を構成しました。脂質異常症治療薬市場は予測期間の10年間に9.4%のCAGRで成長すると予測され、市場規模は2023年までに379億米ドルに達すると見込まれ、ブランド薬の売り上げが269億米ドル (71%) 、ジェネリック薬の売り上げが110億米ドル (29%) を構成すると予測されています。

当レポートでは、世界の脂質異常症 (高脂血症) 市場について調査し、脂質異常症の概要、治療薬の年間市場収益・年間コスト・利用パターンに関するデータ・10年間の予測、アンメットニーズ、R&D・臨床試験の評価、パイプライン分析、および現在・将来の競合状況の分析などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理学
  • 症状
  • 予後
  • 生活の質

第4章 疫学

  • リスク因子・併存疾患
  • 世界・歴史的な動向
    • 米国
    • EU5カ国
    • アジア
  • 予測手法
    • 利用ソース
    • 予測の前提条件・手法
  • 脂質異常症の罹患率
    • 全体罹患率
    • 年齢別罹患率
    • 性別罹患率
    • 年齢調整罹患率
  • 家族性高コレステロール血症の疫学的予測
    • 全体罹患率
  • 高LDLコレステロール血症の疫学的予測
    • 全体罹患率
    • 年齢別罹患率
    • 性別罹患率
    • 年齢調整罹患率
  • 高TG血症 (500mg/dL以上) の疫学的予測
    • 全体罹患率
    • 年齢別罹患率
    • 性別罹患率
    • 年齢調整罹患率
  • 議論

第5章 疾病管理

  • 診断・治療の概要
    • 治療ガイドライン・主な処方薬
    • 臨床診療
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国

第6章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド
    • スタチン
    • ゼチーア (エゼチミブ)
    • Vytorin (シンバスタチン/エゼチミブ)
    • Liptruzet (アトルバスタチン/エゼチミブ)
    • ナアスパン (ナイアシン徐放性)
    • Kynamro (ミポメルセンナトリウム)
    • Juxtapid (ロミタピド)
    • TriCor/Trilipix (フェノフィブラート/fenfibric acid)
    • オメガ3脂肪酸
    • Welchol (コレセベラム) および the Bile Acid Sequestrants

第7章 アンメットニーズ・機会

  • 概要
  • スタチン不耐性・スタチン不応性患者へのLDC-C降下剤
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 診断・患者教育・長期的コンプライアンスの向上
  • アテローム性動脈硬化性プラークの防止または蓄積を無効にする治療薬
  • 副作用改善のプロファイルを持つHoFH (ホモ接合型家族性高コレステロール血症) 患者向けの治療

第8章 パイプライン評価

  • 概要
  • 臨床試験マッピング
  • 臨床開発中の有望な薬剤
    • Alirocumab
    • Bococizumab
    • Evolocumab
    • Anacetrapib
    • Evacetrapib
    • TA-8995 (DEZ-001)
    • CER-001
    • ETC-1002
  • その他の開発中の薬剤

第9章 現在・将来の企業

  • 概要
  • 企業戦略における動向
  • 企業プロファイル
    • AbbVie
    • Aegerion Pharmaceuticals, Inc.
    • Amarin
    • Amgen
    • AstraZeneca
    • Cerenis Therapeutics Inc.
    • 第一三共
    • Dezima Pharma
    • Eli Lilly
    • Esperion Therapeutics, Inc.
    • Genzyme
    • GlaxoSmithKline
    • Merck & Co.
    • Pfizer
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi

第10章 市場展望

  • 世界市場
    • 予測
    • 促進因子・阻害因子
  • 米国
  • EU5カ国
  • 日本
  • 中国

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. GlobalData expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in the dyslipidemia market in the 7MM, reaching peak sales of $9.5B in 2025.

Major drivers of Dyslipidemia market growth over the forecast period are -

  • The launches of three PCSK9 inhibitors-Amgen's Repatha, Sanofi and Regeneron's Praluent, and Eli Lilly's LY3015014-which will significantly boost market growth.
  • The launch of several add-on therapies, including Esperion Therapeutic's ETC-1002 and Merck and Amgen's cholesteryl ester transfer protein (CETP) inhibitors
  • Increase in global prevalence of dyslipidemia, coupled with growing awareness of the disease.

Although the dyslipidemia market has numerous well-established therapies and the pipeline is promising, there is a considerable level of unmet need. Patient compliance, cost-effective therapies, and drugs targeting rare diseases represent major unmet needs in the dyslipidemia space. Patient compliance remains the biggest issue, and a major contributing factor to this is the asymptomatic nature of this disease, as well as the burden of taking several pills daily to treat this disease.

In addition to this, many patients discontinue therapy, which puts them at considerable risk of experiencing a CV event. The PCSK9 monoclonal antibodies (mAbs), Repatha and Praluent, are expected to address the compliance issue due to their less frequent dosing schedules; however, KOLs indicated that patient education and enhanced disease awareness are important issues that also need to be addressed. While patient education is not a common area of focus for pharmaceutical companies, it's clear that if diagnosis rates and patient compliance were increased, then this would translate to a boost in drug use and sales.

Companies reviewed in this report: Abbvie, Aegerion Pharmaceuticals Inc., Akcea Therapeutics Inc., Amarin, Amgen, AstraZeneca, Cerenis Therapeutics Inc., Daiichi Sankyo, Eli Lilly, Esperion Therapeutics Inc., Genzyme, Ionis Pharmaceuticals, Merck & Co., Regeneron Pharmaceuticals Inc., Sanofi, The Medicine Company.

Scope

  • Overview of dyslipidemia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized dyslipidemia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the dyslipidemia therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the dyslipidemia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dyslipidemia therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM dyslipidemia therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 10

  • 1.1 List of Tables 19
  • 1.2 List of Figures 24

2 Introduction 26

  • 2.1 Catalyst 26
  • 2.2 Related Reports 27

3 Disease Overview 28

  • 3.1 Etiology and Pathophysiology 28
    • 3.1.1 Etiology 28
    • 3.1.2 Pathophysiology 30
  • 3.2 Symptoms 34
  • 3.3 Prognosis 34
  • 3.4 Quality of Life 34

4 Epidemiology 35

  • 4.1 Disease Background 35
  • 4.2 Risk Factors and Comorbidities 35
  • 4.3 Global Trends 37
  • 4.4 Forecast Methodology 37
    • 4.4.1 Sources Used Tables 37
    • 4.4.2 Forecast Assumptions and Methods 42
    • 4.4.3 Sources Not Used 58
  • 4.5 Epidemiological Forecast for Dyslipidemia (2015-2025) 59
    • 4.5.1 Dyslipidemia 59
    • 4.5.2 Familial Hypercholesterolemia 63
    • 4.5.3 Increased Low-Density Lipoprotein Cholesterol 64
    • 4.5.4 High Triglycerides 69
    • 4.5.5 Very High Triglycerides 74
    • 4.5.6 Low High-Density Lipoprotein Cholesterol 76
  • 4.6 Discussion 81
    • 4.6.1 Epidemiological Forecast Insight 81
    • 4.6.2 Limitations of the Analysis 83
    • 4.6.3 Strengths of the Analysis 84

5 Disease Management 85

  • 5.1 Diagnosis and Treatment Overview 85
    • 5.1.1 Diagnosis 85
    • 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 87
    • 5.1.3 Clinical Practice 90
  • 5.2 US 92
  • 5.3 5EU 94
  • 5.4 Japan 97

6 Competitive Assessment 99

  • 6.1 Overview 99
  • 6.2 Statins 102
    • 6.2.1 Overview of drug class 102
    • 6.2.2 Crestor (Rosuvastatin) 104
  • 6.3 Zetia (Ezetimibe) 110
    • 6.3.1 Overview 110
    • 6.3.2 Efficacy 113
    • 6.3.3 Safety 114

6.3.4 SWOT Analysis 116

    • 6.3.5 Forecast 116
  • 6.4 Praluent (Alirocumab) 117
    • 6.4.1 Overview 117
    • 6.4.2 Efficacy 120
    • 6.4.3 Safety 122

6.4.4 SWOT Analysis 123

    • 6.4.5 Forecast 124
  • 6.5 Repatha (Evolocumab) 125
    • 6.5.1 Overview 125
    • 6.5.2 Efficacy 127
    • 6.5.3 Safety 130

6.5.4 SWOT Analysis 131

    • 6.5.5 Forecast 132
  • 6.6 Vytorin (Simvastatin/Ezetimibe) 132
    • 6.6.1 Overview 132
    • 6.6.2 Efficacy 134
    • 6.6.3 Safety 135

6.6.4 SWOT Analysis 135

    • 6.6.5 Forecast 136
  • 6.7 Kynamro (Mipomersen) 136
    • 6.7.1 Overview 136
    • 6.7.2 Efficacy 138
    • 6.7.3 Safety 139

6.7.4 SWOT Analysis 141

    • 6.7.5 Forecast 141
  • 6.8 Juxtapid (Lomitapide) 142
    • 6.8.1 Overview 142
    • 6.8.2 Efficacy 144
    • 6.8.3 Safety 146

6.8.4 SWOT Analysis 147

    • 6.8.5 Forecast 147
  • 6.9 Niacin/Nicotinic Acid 148
    • 6.9.1 Overview 148
    • 6.9.2 Efficacy 150
    • 6.9.3 Safety 152

6.9.4 SWOT Analysis 153

    • 6.9.5 Forecast 153
  • 6.10 Fibrates 153
    • 6.10.1 Overview of Drug Class 153
    • 6.10.2 Tricor/Trilipix (Fenofibrate/Fenofibric acid) 155
  • 6.11 Omega-3 Fatty Acids 159
    • 6.11.1 Overview 159
    • 6.11.2 Lovaza (omega-3 acid ethyl esters) 160
    • 6.11.3 Vascepa (Icosapent Ethyl) 163
    • 6.11.4 Epanova (omega-3 carboxylic acids) 168
  • 6.12 Bile Acid Sequestrants 172
    • 6.12.1 Overview 172
    • 6.12.2 Efficacy 174
    • 6.12.3 Safety 174

6.12.4 SWOT Analysis 175

    • 6.12.5 Forecast 175

7 Unmet Needs Assessment and Opportunity Analysis 176

  • 7.1 Overview 176
  • 7.2 Therapies that Target Lipoprotein(a) 178
    • 7.2.1 Unmet Need 178
    • 7.2.2 Gap Analysis 179
    • 7.2.3 Opportunity 180
  • 7.3 Cost-Effective Therapies for Dyslipidemia 180
    • 7.3.1 Unmet Need 180
    • 7.3.2 Gap Analysis 181
    • 7.3.3 Opportunity 181
  • 7.4 Efficacious TG-Lowering Therapies 182
    • 7.4.1 Unmet Need 182
    • 7.4.2 Gap Analysis 183
    • 7.4.3 Opportunity 184
  • 7.5 Improved Diagnosis, Patient Education, and Long-Term Compliance 185
    • 7.5.1 Unmet Need 185
    • 7.5.2 Gap Analysis 187
    • 7.5.3 Opportunity 188
  • 7.6 HoFH Therapies with Reduced Side Effects 189
    • 7.6.1 Unmet Need 189
    • 7.6.2 Gap Analysis 190
    • 7.6.3 Opportunity 191
  • 7.7 Therapies that Prevent or Reverse the Buildup of Atherosclerotic Plaque 191
    • 7.7.1 Unmet Need 191
    • 7.7.2 Gap Analysis 192
    • 7.7.3 Opportunity 193

8 Pipeline Assessment 194

  • 8.1 Overview 194
  • 8.2 Promising Drugs in Clinical Development 195
    • 8.2.1 LY3015014 197
    • 8.2.2 Anacetrapib 202
    • 8.2.3 AMG-899 (TA-8995/DEZ-001) 210
    • 8.2.4 Bempedoic Acid (ETC-1002) 216
    • 8.2.5 Volanesorsen 223
    • 8.2.6 CER-001 228
    • 8.2.7 ALN-PCSsc 233
    • 8.2.8 Gemcabene 238
    • 8.2.9 Pemafibrate (K-877) 243
  • 8.3 Other Drugs in Development 248

9 Current and Future Players 250

  • 9.1 Overview 250
  • 9.2 Trends in Corporate Strategy 253
  • 9.3 Company Profiles 255
    • 9.3.1 AbbVie 255
    • 9.3.2 Aegerion Pharmaceuticals, Inc. 257
    • 9.3.3 Akcea Therapeutics, Inc. and Ionis Pharmaceuticals 258
    • 9.3.4 Amarin 260
    • 9.3.5 Amgen 262
    • 9.3.6 AstraZeneca 263
    • 9.3.7 Cerenis Therapeutics, Inc. 265
    • 9.3.8 Daiichi Sankyo 266
    • 9.3.9 Eli Lilly 267
    • 9.3.10 Esperion Therapeutics, Inc. 269
    • 9.3.11 Genzyme 270
    • 9.3.12 Merck & Co. 272
    • 9.3.13 Regeneron Pharmaceuticals, Inc. 274
    • 9.3.14 Sanofi 275
    • 9.3.15 The Medicines Company 277

10 Market Outlook 280

  • 10.1 Global Markets 280
    • 10.1.1 Forecast 280
    • 10.1.2 Drivers and Barriers - Global Issues 285
  • 10.2 US 290
    • 10.2.1 Forecast 290
    • 10.2.2 Key Events 293
    • 10.2.3 Drivers and Barriers 294
  • 10.3 5EU 296
    • 10.3.1 Forecast 296
    • 10.3.2 Key Events 298
    • 10.3.3 Drivers and Barriers 299
  • 10.4 Japan 302
    • 10.4.1 Forecast 302
    • 10.4.2 Key Events 304
    • 10.4.3 Drivers and Barriers 305

11 Appendix 308

  • 11.1 Bibliography 308
  • 11.2 Abbreviations 332
  • 11.3 Methodology 338
  • 11.4 Forecasting Methodology 338
    • 11.4.1 Diagnosed Dyslipidemia Patients 338
    • 11.4.2 Percent Drug-Treated Patients 339
    • 11.4.3 Drugs Included in Each Therapeutic Class 339
    • 11.4.4 Launch and Patent Expiry Dates 340
    • 11.4.5 General Pricing Assumptions 341
    • 11.4.6 Individual Drug Assumptions 342
    • 11.4.7 Generic Erosion 348
    • 11.4.8 Pricing of Pipeline Agents 348
  • 11.5 Primary Research - KOLs Interviewed for this Report 349
  • 11.6 Primary Research - Prescriber Survey 351
  • 11.7 About the Authors 352
    • 11.7.1 Analyst 352
    • 11.7.2 Therapy Area Director 352
    • 11.7.3 Epidemiologist 353
    • 11.7.4 Director of Epidemiology 353
    • 11.7.5 Global Director of Therapy Analysis and Epidemiology 354
  • 11.8 About GlobalData 355
  • 11.9 Disclaimer 355

List of Tables

1.1 List of Tables

  • Table 1: Dyslipidemia: Fredrickson Classification System 28
  • Table 2: Risk Factors and Comorbidities for Dyslipidemia 36
  • Table 3: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia 38
  • Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH 39
  • Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C 40
  • Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG 41
  • Table 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C 42
  • Table 8: 8MM, Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025 60
  • Table 9: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025 62
  • Table 10: 8MM, Total Prevalent Cases of Increased LDL-C, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025 65
  • Table 11: 8MM, Total Prevalent Cases of High TG, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025 70
  • Table 12: 8MM, Total Prevalent Cases of Very High TG, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025 75
  • Table 13: 8MM, Total Prevalent Cases of Low HDL-C, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025 77
  • Table 14: AACE Optimal/Near-Optimal, Borderline, and High-Risk Serum Lipid Concentrations 85
  • Table 15: Factors Considered for Different CVD Risk Calculators 86
  • Table 16: Treatment Guidelines for Dyslipidemia 88
  • Table 17: Most Prescribed Drugs for Dyslipidemia by Class in the Global Markets, 2015 90
  • Table 18: Country Profile - US 93
  • Table 19: Market Profile - 5EU 95
  • Table 20: Country Profile - Japan 98
  • Table 21: Intensity level of commonly used statins 103
  • Table 22: Product Profile - Crestor (Rosuvastatin) 106
  • Table 23: Efficacy of Rosuvastatin - Lipid and Lipoprotein Parameters 107
  • Table 24: Crestor SWOT Analysis, 2015 109
  • Table 25: Product Profile - Zetia 112
  • Table 26: Efficacy of Zetia - Primary and Secondary Endpoints, IMPROVE-IT study 114
  • Table 27: Safety of Zetia (Ezetimibe) 115
  • Table 28: Drug Zetia (Ezetimibe) SWOT Analysis, 2015-2025 116
  • Table 29: Product Profile - Praluent 120
  • Table 30: Efficacy of Praluent (alirocumab) - Primary and Secondary Endpoints, ODYSSEY LONG TERM Phase III Study 121
  • Table 31: Safety of Praluent (alirocumab) 122
  • Table 32: Praluent (Alirocumab) SWOT Analysis, 2015-2025 123
  • Table 33: Product Profile - Repatha 127
  • Table 34: Pivotal Trials of Repatha (Evolocumab) 128
  • Table 35: Repatha (Evolocumab) SWOT Analysis, 2015-2025 131
  • Table 36: Product Profile - Vytorin 133
  • Table 37: Efficacy of Vytorin - Primary and Secondary Endpoints, VYVA study 134
  • Table 38: Vytorin SWOT Analysis, 2015 135
  • Table 39: Product Profile - Kynamro 138
  • Table 40: Efficacy of Kynamro - Lipid and Lipoprotein Parameters, RADICHOL 1 Phase III Study 139
  • Table 41: Safety of Kynamro (mipomersen) 140
  • Table 42: Kynamro SWOT Analysis, 2015 141
  • Table 43: Product Profile - Juxtapid 144
  • Table 44: Efficacy of Juxtapid - Lipid and Lipoprotein parameters, Phase III Study 145
  • Table 45: Juxtapid SWOT Analysis, 2015 147
  • Table 46: Product Profile - Niaspan 150
  • Table 47: Niacin/Nicotinic Acid SWOT Analysis, 2015 153
  • Table 48: Summary of the Therapeutic Properties of Fibrates* 154
  • Table 49: Product Profile - Tricor/Trilipix 156
  • Table 50: Tricor/Trilipix SWOT Analysis, 2015 158
  • Table 51: Product Profile - Lovaza 161
  • Table 52: Efficacy of Lovaza - Pivotal Studies for the Treatment of Very High TGs 162
  • Table 53: Lovaza SWOT Analysis, 2015 163
  • Table 54: Product Profile - Vascepa 165
  • Table 55: Efficacy of Vascepa - ANCHOR Phase III Study 166
  • Table 56: Vascepa SWOT Analysis, 2015 167
  • Table 57: Product Profile - Epanova 169
  • Table 58: Efficacy of Epanova - ESPRIT Phase III Study 170
  • Table 59: Epanova SWOT Analysis, 2015 171
  • Table 60: Product Profile - Welchol 173
  • Table 61: Efficacy of Welchol - GLOWS Study 174
  • Table 62: Welchol SWOT Analysis, 2015 175
  • Table 63: Unmet Need and Opportunity in Dyslipidemia, 2015 178
  • Table 64: Product Profile - LY3015014 198
  • Table 65: Efficacy of LY3015014 199
  • Table 66: LY3015014 SWOT Analysis, 2015 201
  • Table 67: Product Profile - Anacetrapib 205
  • Table 68: Efficacy of Anacetrapib - Primary and Secondary Endpoints, DEFINE study 206
  • Table 69: Safety of Anacetrapib - AEs and Safety Variables, DEFINE study 207
  • Table 70: Anacetrapib SWOT Analysis, 2015 209
  • Table 71: Product Profile - AMG-899 ( TA-8995/DEZ-001) 211
  • Table 72: Efficacy of TA-8995 - Primary Endpoints, TULIP study 213
  • Table 73: AMG-899 SWOT Analysis, 2015 215
  • Table 74: Product Profile - ETC-1002 (Bempedoic Acid) 218
  • Table 75: Efficacy of ETC-1002 - Lipid and lipoprotein parameters 220
  • Table 76: ETC-1002 SWOT Analysis, 2015 222
  • Table 77: Product Profile - Volanesorsen 224
  • Table 78: Efficacy of Volanesorsen - Lipid and Lipoprotein Levels and Glycemic Control 225
  • Table 79: Volanesorsen SWOT Analysis, 2015 227
  • Table 80: Product Profile - CER-001 229
  • Table 81: Efficacy of CER-001 230
  • Table 82: CER-001 SWOT Analysis, 2015 232
  • Table 83: Product Profile - ALN-PCSsc 234
  • Table 84: ALN-PCSsc SWOT Analysis, 2015 237
  • Table 85: Product Profile - Gemcabene 239
  • Table 86: Efficacy of Gemcabene 240
  • Table 87: Gemcabene SWOT Analysis, 2015 242
  • Table 88: Product Profile - Pemafibrate 244
  • Table 89: Efficacy of Pemafibrate 245
  • Table 90: Safety of Pemafibrate 246
  • Table 91: Pemafibrate SWOT Analysis, 2015 247
  • Table 92: Drugs in Development for Dyslipidemia, 2015 249
  • Table 93: Key Companies in the Dyslipidemia Market in the 7MM, 2015 252
  • Table 94: Abbvie's Dyslipidemia Portfolio Assessment, 2015 257
  • Table 95: Aegerion Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015 258
  • Table 96: Ionis Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015 260
  • Table 97: Amarin's Dyslipidemia Portfolio Assessment, 2015 262
  • Table 98: Amgen's Dyslipidemia Portfolio Assessment, 2015 263
  • Table 99: AstraZeneca's Dyslipidemia Portfolio Assessment, 2015 264
  • Table 100: Cerenis Therapeutics' Dyslipidemia Portfolio Assessment, 2015 266
  • Table 101: Daiichi Sankyo's Dyslipidemia Portfolio Assessment, 2015 267
  • Table 102: Eli Lilly's Dyslipidemia Portfolio Assessment, 2015 269
  • Table 103: Esperion Therapeutics' Dyslipidemia Portfolio Assessment, 2015 270
  • Table 104: Genzyme's Dyslipidemia Portfolio Assessment, 2015 272
  • Table 105: Merck & Co.'s Dyslipidemia Portfolio Assessment, 2015 273
  • Table 106: Regeneron Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015 275
  • Table 107: Sanofi's Dyslipidemia Portfolio Assessment, 2015 277
  • Table 108: The Medicines Company's Dyslipidemia Portfolio Assessment, 2015 279
  • Table 109: Dyslipidemia Market - Global Drivers and Barriers, 2015?2025 285
  • Table 110: Key Events Impacting Sales for Dyslipidemia in the US, 2015-2025 293
  • Table 111: Dyslipidemia Market - Drivers and Barriers in the US, 2015?2025 294
  • Table 112: Key Events Impacting Sales for Dyslipidemia in the 5EU, 2015-2025 298
  • Table 113: Dyslipidemia Market - Drivers and Barriers in the 5EU, 2015?2025 299
  • Table 114: National Healthcare Authorities in the 5EU Nations 299
  • Table 115: National Public Health Initiatives in the 5EU Nations 300
  • Table 116: Governmental Drug Pricing Authorities in the 5EU Nations 301
  • Table 117: Key Events Impacting Sales for Dyslipidemia in Japan, 2015-2025 304
  • Table 118: Dyslipidemia Market - Drivers and Barriers in Japan, 2015?2025 305
  • Table 119: Key Launch Dates for Dyslipidemia 340
  • Table 120: Key Patent Expiry Dates for Dyslipidemia 340
  • Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 351

List of Figures

1.2 List of Figures

  • Figure 1: Classification of Dyslipidemia 30
  • Figure 2: 8MM Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, 2015-2025 61
  • Figure 3: 8MM Diagnosed Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, 2015-2025 63
  • Figure 4: 8MM, Total Prevalent Cases of FH, Both Sexes, Ages ≥20 Years, N, 2015 and 2025 64
  • Figure 5: 8MM, Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, N, 2015 and 2025 66
  • Figure 6: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, N, 2015 67
  • Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, 2015 68
  • Figure 8: 8MM, Age-Standardized Total Prevalence of Increased LDL-C, Both Sexes, Ages ≥20 Years, 2015 69
  • Figure 9: 8MM, Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, N, 2015-2025 71
  • Figure 10: 8MM, Sex-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, N, 2015 72
  • Figure 11: 8MM, Age-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, 2015 73
  • Figure 12: 8MM, Age-Standardized Total Prevalence of High TG, Both Sexes, Ages ≥20 Years, 2015 74
  • Figure 13: 8MM, Total Prevalent Cases of Very High TG, Both Sexes, Ages ≥20 Years, N, 2015-2025 76
  • Figure 14: 8MM, Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ≥20 Years, N, 2015-2025 78
  • Figure 15: 8MM, Sex-Specific Total Prevalent Cases of Low HDL-C, Ages ≥20 Years, N, 2015 79
  • Figure 16: 8MM, Age-Specific Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ≥20 Years, 2015 80
  • Figure 17: 8MM, Age-Standardized Total Prevalence of Low HDL-C, Both Sexes, Ages ≥20 Years, 2015 81
  • Figure 18: Statin Mechanism of Action 103
  • Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Dyslipidemia, 2015-2025 197
  • Figure 20: ACL inhibition 217
  • Figure 21: Company Portfolio Gap Analysis in Dyslipidemia, 2015-2025 253
  • Figure 22: Global Sales for Dyslipidemia by Region, 2015 and 2025 283
  • Figure 23: Global Sales for Dyslipidemia by Drug Class, 2015 and 2025 284
  • Figure 24: Global Sales for PCSK9 targeting therapies, 2015-2025 285
  • Figure 25: Sales for Dyslipidemia by Drug Class in the US, 2015 and 2025 292
  • Figure 26: Sales for Dyslipidemia by Drug Class in the 5EU, 2015 and 2025 297
  • Figure 27: Sales for Dyslipidemia by Drug Class in Japan, 2015 and 2025 303
Back to Top